Brief: Eloxx Pharma Resumes Enrollment In U.S. Phase 2 Clinical Trial In Cystic Fibrosis
12/08/2020 12:45
Aug 12 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ENROLLMENT IN THE U.S. PHASE 2 CLINICAL TRIAL IN CYSTIC
FIBROSIS
HAS RESUMED AFTER BEING PAUSED IN RESPONSE TO THE COVID-19
PANDEMIC
* ELOXX PHARMACEUTICALS - ENROLLMENT RESUMED IN PHASE 2
TRIAL FOR
ELX-02 IN CYSTIC FIBROSIS AT CERTAIN U.S. SITES AFTER BEING
TEMPORARILY PAUSED
Source text for Eikon: ID:nGNX5v5bCl
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome